FATE THERAPEUTICS INC
No SEC Form 4 filings for $FATE in the last 30 days.
See all $FATE insider activity →Fate Therapeutics (FATE) received a $15M grant from CIRM to advance FT819 in a Phase 2 trial for lupus nephritis. The RECLAIM-LN study will evaluate the off-the-shelf CAR T-cell therapy in 53 patients. Preliminary data showed favorable safety and disease activity improvements. FATE's stock closed at $2.33, up 4.72% in pre-market trading.
Fate Therapeutics (FATE) will present four abstracts at ACR Convergence 2026, showcasing data on its FT819 and FT839 CAR T-cell candidates for autoimmune diseases. FT819 data includes updates on outpatient administration and quality-of-life improvements. FT839 data covers preclinical studies and Phase 1/2 trial progress. FATE stock closed at $2.35, up 0.43%, and is trading at $2.40 in premarket.
U.S. stock indices rose on Thursday, led by chipmaker stocks, with S&P 500 up 0.8%, Nasdaq 100 up 1.3%, and Dow Jones up 0.3%. Investors focused on SK Hynix's upcoming Nasdaq debut and upcoming earnings season. Oracle was downgraded by S&P Global Ratings, Starbucks is using AI to reduce reliance on legacy tech, TeraWulf plans $3.5B debt raise, Palo Alto Networks CEO commented on AI token prices, and Fate Therapeutics received FDA clearance for a clinical trial.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FATE (FATE THERAPEUTICS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent FATE coverage spans technology, market movers and earnings.
The grant provides non-dilutive funding for a potentially registrational trial, reducing cash burn and de‑risking the program.
Positive exposure at a major rheumatology conference may boost investor sentiment and support near‑term price appreciation.
Regulatory clearance may drive upside for the biotech.
First-patient dosing advances FT819 toward a potentially accelerated regulatory pathway (RMAT, FDA CMC pilot), improving near-term clinical momentum visibility.
Near-term sentiment should skew positive on the RECLAIM-LN dosing milestone, while investors will also focus on funding runway and trial execution into 1H 2028.
AlphAI scores every news story that mentions FATE with an AI model for sentiment and relevance, and aggregates insider trades from FATE THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Fate Therapeutics (FATE) received a $15M grant from CIRM to advance FT819 in a Phase 2 trial for lupus nephritis. The RECLAIM-LN study will evaluate the off-the-shelf CAR T-cell therapy in 53 patients. Preliminary data showed favorable safety and disease activity improvements. FATE's stock closed at $2.33, up 4.72% in pre-market trading.
2 min readFate Therapeutics (FATE) will present four abstracts at ACR Convergence 2026, showcasing data on its FT819 and FT839 CAR T-cell candidates for autoimmune diseases. FT819 data includes updates on outpatient administration and quality-of-life improvements. FT839 data covers preclinical studies and Phase 1/2 trial progress. FATE stock closed at $2.35, up 0.43%, and is trading at $2.40 in premarket.
1 min readU.S. stock indices rose on Thursday, led by chipmaker stocks, with S&P 500 up 0.8%, Nasdaq 100 up 1.3%, and Dow Jones up 0.3%. Investors focused on SK Hynix's upcoming Nasdaq debut and upcoming earnings season. Oracle was downgraded by S&P Global Ratings, Starbucks is using AI to reduce reliance on legacy tech, TeraWulf plans $3.5B debt raise, Palo Alto Networks CEO commented on AI token prices, and Fate Therapeutics received FDA clearance for a clinical trial.
2 min readFate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.
4 min readFATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated
6 min readValamehr Bahram (President and CEO) sold 43,947 shares of FATE THERAPEUTICS INC (FATE) at $2.46 ($0.11M total) on 2026-08-04.
2 min readFate Therapeutics (NASDAQ: FATE) said it granted inducement awards on Aug. 1, 2026 under Nasdaq Rule 5635(c)(4). One new non-executive employee received non-qualified stock options for 37,300 shares at $2.45 per share. Two employees received RSUs for 45,300 shares. Options and RSUs vest over four years.
2 min readFate Therapeutics (NASDAQ: FATE) said the FDA cleared its IND for FT839, an off-the-shelf dual CAR T-cell candidate targeting CD19 and CD38. The company plans a Phase 1/2 multi-indication basket trial starting in 2H 2026 to test FT839 with standard-of-care for autoimmune diseases, with or without conditioning chemotherapy. Key initial indications include rheumatoid arthritis and lupus.
3 min readFate Therapeutics (NASDAQ: FATE) said it will present preliminary Phase 1 basket-trial data for its off-the-shelf CD19 CAR T-cell FT819 in systemic sclerosis at the ISSCR 2026 meeting (July 8–11). As of June 12, four patients showed rCRISS25+ and mean mRSS improvement at 3 months, with no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths reported.
4 min readFATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 fate-ex10_1.htm EX-10.1 EX-10.1 FATE THERAPEUTICS, INC. THIRD AMENDED AND RESTATED 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Fate Therapeutics, Inc. Third Amended and Restated 2022 Stock Option a
3 min read
